Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

Published:2017-10-26 Issue:3 Volume:124 Page:587-595
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop M.¹^ORCID,Mamolo Carla M.²,Gambacorti-Passerini Carlo³,Cortes Jorge E.¹,Brümmendorf Tim H.⁴⁵,Su Yun⁶,Reisman Arlene L.⁶,Shapiro Mark⁷,Lipton Jeff H.⁸

Affiliation:

1. The University of Texas MD Anderson Cancer Center; Houston Texas

2. Pfizer Inc; Groton Connecticut

3. University of Milano-Bicocca; Monza Italy

4. Hubertus Wald Tumor Center; University Cancer Center Hamburg; Hamburg Germany

5. University Hospital, Rheinisch-Westfälische Technische Hochscule; Aachen Germany

6. Pfizer Inc; New York New York

7. Pfizer Inc; Cambridge Massachusetts

8. Princess Margaret Cancer Centre; Toronto Ontario Canada

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.31082/fullpdf

Reference26 articles.

1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med.,2003

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med.,2006

3. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION);Kantarjian;Blood.,2012

4. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up;Larson;Leukemia.,2012

5. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy;Hochhaus;Blood.,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-01

2. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study;Leukemia;2023-11-25

3. Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML;Leukemia & Lymphoma;2023-04-05

4. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option;Blood Reviews;2022-11

5. Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review;Journal of Comparative Effectiveness Research;2022-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3